{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:45:05Z","timestamp":1794051905815,"version":"4.8.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Real-world data regarding hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients receiving tenofovir alafenamide (TAF) as an antiviral drug are limited. Hence, we evaluated the efficacy and kidney safety of TAF among this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 272 HBV-related ACLF patients hospitalized at Xiangya Hospital of Central South University were enrolled in this retrospective research. All patients received antiviral therapy with TAF (<jats:italic>n<\/jats:italic> = 100) or ETV (<jats:italic>n<\/jats:italic> = 172) and comprehensive medical treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Through 1:1 propensity score matching, 100 patients were finally included in each group. At week 48, the survival rates without transplantation of the TAF group and ETV group were 76.00 and 58.00%, separately (<jats:italic>P<\/jats:italic> = 0.007). After 4 weeks of treatment, the TAF treatment group exhibited a significantly decline in HBV DNA viral load (<jats:italic>P<\/jats:italic> = 0.029). The mean estimated glomerular filtration rate was apparently improved in the TAF group compared with the ETV group (TAF 5.98 \u00b1 14.46 vs. ETV 1.18 \u00b1 18.07 ml\/min\/1.73 m<jats:sup>2<\/jats:sup>) (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). There were 6 patients in TAF group and 21 patients in ETV group with chronic kidney disease (CKD) stage progression \u2265 1. By contrast, the ETV treatment group has a greater risk of renal function progression in CKD 1 stage patients (<jats:italic>P<\/jats:italic> &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This real-world clinical study showed that TAF is more effective than ETV in reducing viral load and improving survival rate in HBV-ACLF patients and the risk of renal function decline is lower.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>https:\/\/ClinicalTrials.gov<\/jats:ext-link>, identifier NCT05453448.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2023.1185492","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T12:35:32Z","timestamp":1685018132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study"],"prefix":"10.3389","volume":"14","author":[{"given":"Wenting","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cichun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/gutjnl-2014-307526","article-title":"Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis.","volume":"64","author":"Angeli","year":"2015","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis.","volume":"74","author":"Arroyo","year":"2021","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14309\/ajg.0000000000001595","article-title":"Acute-on-Chronic Liver Failure Clinical Guidelines.","volume":"117","author":"Bajaj","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/MNH.0000000000000392","article-title":"Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.","volume":"27","author":"Chan","year":"2018","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/gutjnl-2016-312670","article-title":"Acute-on-chronic liver failure: an update.","volume":"66","author":"Hernaez","year":"2017","journal-title":"Gut"},{"key":"B9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12664-012-0295-9","article-title":"Etiology, clinical profile, and inhospital mortality of acute-on-chronic liver failure: a prospective study.","volume":"32","author":"Jha","year":"2013","journal-title":"Indian J. Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.cgh.2021.05.032","article-title":"Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B.","volume":"20","author":"Jung","year":"","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/liv.15208","article-title":"Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B.","volume":"42","author":"Jung","year":"","journal-title":"Liver Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06237-x","article-title":"Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.","volume":"21","author":"Li","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/gutjnl-2020-323395","article-title":"PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.","volume":"71","author":"Li","year":"2022","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/jvh.13222","article-title":"An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate.","volume":"27","author":"Lim","year":"2020","journal-title":"J. Viral Hepat."},{"key":"B16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1586\/17474124.2014.909724","article-title":"Current developments in nucleoside\/nucleotide analogues for hepatitis B.","volume":"8","author":"Lo","year":"2014","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s12072-015-9653-x","article-title":"AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis.","volume":"9","author":"Maiwall","year":"2015","journal-title":"Hepatol. Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.","volume":"31","author":"Malinchoc","year":"2000","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy.","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jceh.2015.08.002","article-title":"Acute-on-Chronic Liver Failure (ACLF) in Coastal Eastern India: \u201cA Single-Center Experience\u201d.","volume":"6","author":"Pati","year":"2016","journal-title":"J. Clin. Exp. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/QAD.0000000000002699","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials.","volume":"34","author":"Pilkington","year":"2020","journal-title":"AIDS"},{"key":"B22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/ckj\/sfx026","article-title":"Age-dependent reference intervals for estimated and measured glomerular filtration rate.","volume":"10","author":"Pottel","year":"2017","journal-title":"Clin. Kidney J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.","volume":"13","author":"Sarin","year":"2019","journal-title":"Hepatol. Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection.","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00535-014-1011-6","article-title":"Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy.","volume":"50","author":"Tada","year":"2015","journal-title":"J. Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/apt.14497","article-title":"Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B.","volume":"47","author":"Wong","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.hbpd.2021.05.010","article-title":"Progress in hepatitis B virus-related acute-on-chronic liver failure treatment in China: A large, multicenter, retrospective cohort study using a propensity score matching analysis.","volume":"20","author":"Xiao","year":"2021","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jvh.13468","article-title":"The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.","volume":"28","author":"Zhang","year":"2021","journal-title":"J. Viral Hepat."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1185492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T12:35:34Z","timestamp":1685018134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1185492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":29,"alternative-id":["10.3389\/fmicb.2023.1185492"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2023.1185492","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"article-number":"1185492"}}